apn-1607-tau-pet-phase3-nct07422857

Migration, Crosslink

📖

apn-1607-tau-pet-phase3-nct07422857

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-apn-1607-tau-pet-ph

📖 Wiki Page

clinical_trial2900 wordssynced 2026-04-02

APN-1607 Tau PET Phase 3 Trial (NCT07422857)

Overview

flowchart TD apn_1607_tau_pet_phase3_nct074["apn-1607-tau-pet-phase3-nct07422857"] apn_1607_tau_pet_phase3_nct074["APN-1607"] apn_1607_tau_pet_phase3_nct074 -->|"related to"| apn_1607_tau_pet_phase3_nct074 style apn_1607_tau_pet_phase3_nct074 fill:#81c784,stroke:#333,color:#000 apn_1607_tau_pet_phase3_nct074["Phase"] apn_1607_tau_pet_phase3_nct074 -->|"related to"| apn_1607_tau_pet_phase3_nct074 style apn_1607_tau_pet_phase3_nct074 fill:#81c784,stroke:#333,color:#000 apn_1607_tau_pet_phase3_nct074["Trial"] apn_1607_tau_pet_phase3_nct074 -->|"related to"| apn_1607_tau_pet_phase3_nct074 style apn_1607_tau_pet_phase3_nct074 fill:#81c784,stroke:#333,color:#000 style apn_1607_tau_pet_phase3_nct074 fill:#4fc3f7,stroke:#333,color:#000

This Phase 3 trial evaluates [18F]-APN-1607 (also known as Florispir or PM-PBB3), a novel second-generation tau PET tracer developed by [Aprinoia Therapeutics](/organizations/aprinoia-therapeutics), for detecting tau pathology in patients with Alzheimer's disease-related cognitive impairment. The trial represents a critical milestone in bringing advanced tau imaging technology to clinical practice for improved diagnosis and monitoring of neurodegenerative diseases["@aprinoia2024"].

...

APN-1607 Tau PET Phase 3 Trial (NCT07422857)

Overview

Mermaid diagram (expand to render)

This Phase 3 trial evaluates [18F]-APN-1607 (also known as Florispir or PM-PBB3), a novel second-generation tau PET tracer developed by [Aprinoia Therapeutics](/organizations/aprinoia-therapeutics), for detecting tau pathology in patients with Alzheimer's disease-related cognitive impairment. The trial represents a critical milestone in bringing advanced tau imaging technology to clinical practice for improved diagnosis and monitoring of neurodegenerative diseases["@aprinoia2024"].

Tau positron emission tomography (PET) imaging has revolutionized our ability to visualize and quantify tau pathology in vivo, providing unprecedented insights into disease progression and treatment response. Unlike first-generation tau tracers such as flortaucipir (AV-1451), which demonstrate excellent affinity for 3R/4R tau filaments found in Alzheimer's disease, second-generation tracers like APN-1607 offer improved binding characteristics across multiple tauopathy subtypes, making them valuable tools for differential diagnosis and therapeutic development["@fpmpbb3"][@nikolaychuk2023].

Trial Details

| Field | Value |
|-------|-------|
| NCT Number | NCT07422857 |
| Phase | Phase 3 |
| Status | Recruiting |
| Sponsor | Aprinoia Therapeutics |
| Conditions | Alzheimer's Disease, Mild Cognitive Impairment, Alzheimer's Disease-Related Cognitive Impairment |
| Intervention | [18F]-APN-1607 PET imaging |
| Participants | Estimated 300-500 |
| Study Type | Interventional |
| Allocation | Non-randomized |
| Primary Endpoint | Tau binding standardized uptake value ratio (SUVR) in target brain regions |
| Secondary Endpoints | Correlation with cognitive measures, diagnostic accuracy, safety |

Background: Tau PET Imaging in Neurodegeneration

The Importance of Tau Pathology

Tau protein aggregation is a hallmark of numerous neurodegenerative diseases collectively termed tauopathies. In Alzheimer's disease, hyperphosphorylated tau forms neurofibrillary tangles (NFTs) that correlate strongly with cognitive decline and neuronal loss. The spatial progression of tau pathology follows a predictable pattern described by Braak staging, beginning in the entorhinal cortex and hippocampus before spreading to neocortical regions[@leuzy2021].

Beyond Alzheimer's disease, tau pathology characterizes several other conditions:

Progressive Supranuclear Palsy (PSP): 4R tau predominance in subcortical structures
Corticobasal Syndrome (CBS): Asymmetric 4R tau deposition
Frontotemporal Dementia with Tau Pathology (FTD-tau): Various 3R/4R patterns
Chronic Traumatic Encephalopathy (CTE): 3R tau in perivascular regions

Accurate tau imaging enables:

Early and specific diagnosis of tauopathies
Objective measurement of disease progression
Patient selection for disease-modifying therapy trials
Monitoring of treatment response

First-Generation Tau PET Tracers

The first successful tau PET tracer, flortaucipir (also known as AV-1451 or T807), was developed by Avid Radiopharmaceuticals and approved by the FDA for tau imaging in Alzheimer's disease. Flortaucipir demonstrates high affinity for paired helical filament (PHF) tau in AD and shows good correlation with Braak staging and cognitive impairment[@leuzy2021].

However, first-generation tracers have notable limitations:

Limited 4R Tau Binding: Reduced affinity for 4R tau isoforms in PSP, CBD

Off-Target Binding: Significant binding to melanin, blood vessels, and other structures

Signal Quantification Challenges: Complex kinetic modeling requirements

Timing Constraints: Optimal imaging windows vary by region and disease

Second-Generation Tau PET Tracers

Second-generation tracers were developed to address these limitations. APN-1607 (also known as PM-PBB3, Florispir) represents one of the most promising candidates, offering enhanced binding characteristics for both 3R and 4R tau isoforms[@fpmpbb3].

Key Advantages of APN-1607

| Characteristic | First-Generation (Flortaucipir) | Second-Generation (APN-1607) |
|----------------|----------------------------------|-------------------------------|
| 3R/4R Binding | Limited for 4R | High affinity for both |
| Off-Target | Significant melanin binding | Reduced off-target binding |
| Image Quality | Variable | Improved signal-to-background |
| 4R Tauopathies | Limited utility | Clinical utility demonstrated |
| Kinetic Modeling | Complex | Simplified approaches possible |

Mechanism of Action

APN-1607 Binding Characteristics

APN-1607 is a fluorine-18 labeled benzimidazole pyridine derivative that binds with high affinity to tau fibrils. The binding mechanism involves:

Filament Recognition: Specific binding to paired helical filament (PHF) and straight filament (SF) tau aggregates

Conformational Specificity: Recognition of the stacked β-sheet structure characteristic of pathological tau

isoform Binding: Ability to bind both 3R and 4R tau isoforms with high affinity

Selectivity: High ratio of specific to non-specific binding

Preclinical studies demonstrate that APN-1607 exhibits:

IC50 values in nanomolar range for PHF-tau binding
Minimal binding to amyloid-beta plaques
Low affinity for monoamine oxidase (MAO) enzymes
Favorable brain penetration and clearance kinetics[@chen2023]

Signal Generation

Upon intravenous administration, [18F]-APN-1607 crosses the blood-brain barrier and binds to tau deposits in the brain. The fluorine-18 radionuclide (half-life 109.8 minutes) emits positrons that annihilate with electrons, producing detectable gamma rays. The resulting PET images provide:

Regional Tau Burden: Quantification of tau deposition across brain regions
Spatiotemporal Patterns: Visualization of tau spread following disease-specific patterns
Quantitative Metrics: Standardized uptake value ratios (SUVR) for longitudinal tracking

Study Objectives and Endpoints

Primary Endpoints

Tau SUVR Quantification: Measure standardized uptake value ratios in regions of interest (entorhinal cortex, hippocampus, temporal cortex, frontal cortex)

Diagnostic Differentiation: Distinguish AD patients from healthy controls based on tau burden

Clinical Correlation: Establish relationship between PET signal and cognitive performance

Secondary Endpoints

Disease Stage Stratification: Correlate tau burden with disease severity (CDR, MMSE scores)

Amyloid Co-occurrence: Evaluate relationship with amyloid PET findings

Longitudinal Progression: Track changes in tau burden over time

Biomarker Correlation: Compare with CSF and plasma tau biomarkers

Safety Assessment: Monitor for adverse events related to radiation exposure

Exploratory Objectives

Machine Learning Applications: Develop automated quantification algorithms

Subtyping: Identify tau imaging subtypes within AD spectrum

Genetic Interactions: Correlate with APOE genotype and other risk factors

Patient Population

Inclusion Criteria

Age 50-90 years
Clinical diagnosis of AD or MCI due to AD
Cognitive impairment consistent with AD spectrum
Ability to undergo PET scanning
Stable medications for 4 weeks prior to enrollment

Exclusion Criteria

Contraindications to PET imaging
Significant neurological conditions other than AD
Recent participation in other clinical trials
Severe psychiatric conditions
Inability to provide informed consent

Imaging Protocol

PET Acquisition

| Parameter | Specification |
|-----------|---------------|
| Tracer | [18F]-APN-1607 |
| Dose | 185-370 MBq (5-10 mCi) |
| Injection | Intravenous bolus |
| Uptake Time | 90-110 minutes post-injection |
| Scan Duration | 20-30 minutes |
| Reconstruction | OSEM, attenuation correction |
| Resolution | 2-3 mm isotropic |

Quantification Methods

Standardized uptake value ratios (SUVR) are calculated using reference regions[@johnson2023]:

Cerebellar Cortex: Commonly used reference for AD
Entorhinal Cortex: Early AD changes
Whole Cerebellum: Alternative reference
Pons: Alternative for some analyses

Regions of interest include:

Braak regions I-VI
Temporal, frontal, parietal cortices
Hippocampus and entorhinal cortex
Subcortical structures

Clinical Significance

Diagnostic Applications

APN-1607 PET imaging provides clinical utility in several scenarios[@krismer2023]:

Differential Diagnosis: Distinguishing AD from other dementias

-区分AD与血管性痴呆
-区分AD与路易体痴呆
-区分AD与额颞叶痴呆

Early Detection: Identifying tau pathology in preclinical and prodromal stages

MCI conversion prediction
Risk stratification

Disease Staging: Correlating imaging findings with clinical severity

Braak stage estimation
Disease progression monitoring

Therapeutic Development Applications

Tau PET imaging is critical for anti-tau therapeutic development:

Patient Selection: Enriching trials with tau-positive patients

Target Engagement: Demonstrating drug binding to tau pathology

Dose Selection: Identifying optimal dosing for target occupancy

Efficacy Assessment: Monitoring treatment effects on tau burden

Comparison with Other Tracers

| Tracer | Company | Target | Status |
|--------|---------|--------|--------|
| Flortaucipir (AV-1451) | Avid/Lilly | PHF-tau (3R+4R) | Approved |
| MK-6240 | Merck | PHF-tau | Phase 3 |
| PI-2620 | Piramal | 3R/4R tau | Phase 3 |
| APN-1607 | Aprinoia | 3R/4R tau | Phase 3 |
| JNJ-067 | Janssen | PHF-tau | Phase 2 |

Scientific Rationale

Biological Basis for Tau Imaging

The tau protein is a microtubule-associated protein that stabilizes neuronal cytoskeleton. In neurodegeneration, tau becomes hyperphosphorylated, dissociates from microtubules, and forms insoluble aggregates. These aggregates progress through distinct stages:

Early Accumulation: Beginning in entorhinal cortex (Braak I-II)

Limbic Spread: Hippocampal and anterior cingulate involvement (Braak III-IV)

Neocortical Extension: Parietal and frontal cortex involvement (Braak V-VI)

Widespread Deposition: Variable patterns depending on disease subtype

The close correlation between tau burden and cognitive decline makes tau PET an ideal biomarker for:

Disease diagnosis and staging
Prognostic assessment
Treatment response monitoring
Clinical trial endpoint

Technical Advantages of APN-1607

APN-1607 offers several technical advantages over first-generation tracers[@smith2022]:

Broad Tauopathy Coverage: Suitable for both AD (3R+4R) and 4R tauopathies (PSP, CBD)

Reduced Off-Target Binding: Less melanin and blood vessel binding

Improved Kinetics: Faster brain uptake and clearance

Better Signal-to-Background: Higher contrast images

Flexible Imaging Windows: More forgiving timing for image acquisition

Clinical Validation Studies

Phase 1 and 2 Findings

Clinical validation of APN-1607 has demonstrated:

Phase 1 Studies (NCT02869538):

Safe administration at doses up to 370 MBq
Rapid brain uptake (5-10% ID at 5 minutes)
Favorable kinetics with peak uptake at 30-60 minutes
Radiation dosimetry within acceptable limits[@hostetler2023]

Phase 2 Studies (NCT03625128):

High sensitivity for detecting Braak stage I-II tau pathology
Strong correlation with CSF biomarkers
Good test-retest reliability (ICC > 0.90)[@su2023]
Clear differentiation between AD patients and healthy controls

Published Clinical Evidence

Key publications supporting APN-1607 clinical development include:

FPM-PBB3 Characterization (Nature Medicine, 2024): Demonstrated utility in AD and PSP

Clinical Validation (Alzheimer's & Dementia, 2024): Confirmed diagnostic accuracy

CSF Correlation (Annals of Neurology, 2024): Showed correlation with fluid biomarkers

4R Tauopathy Studies (Movement Disorders, 2022): Demonstrated utility in PSP and CBD

Safety Profile

Radiation Considerations

[18F]-APN-1607 exposure involves ionizing radiation:

Effective dose: Approximately 5-7 mSv per scan
Comparable to other diagnostic PET procedures
Subject to standard radiation safety protocols

Adverse Events

Clinical trials to date show:

No serious adverse events attributed to the tracer
Most common events: mild injection site reactions
No significant hemodynamic effects
Well-tolerated in elderly populations

Future Directions

Broader Clinical Applications

Successful Phase 3 completion would enable:

Routine Clinical Use: Integration into diagnostic workup for dementia

Therapeutic Monitoring: Tracking response to anti-tau therapies

Combination with Amyloid Imaging: Comprehensive biomarker assessment

Multi-Center Standardization: Establishing reference databases

Combination with Therapeutic Trials

APN-1607 imaging is being integrated into multiple anti-tau therapeutic trials:

Anti-tau monoclonal antibodies
Tau aggregation inhibitors
Gene therapy approaches
Small molecule modulators

The ability to demonstrate target engagement and monitor treatment effects makes tau PET essential for therapeutic development.

Cross-References

[18F-PM-PBB3 PET Study (NCT03625128)](/clinical-trials/18f-pmbb3-pet-tauopathy-nct03625128)
[Aprinoia Therapeutics](/organizations/aprinoia-therapeutics)
[Tau PET Imaging](/diagnostics/pet-imaging)
[Tau Pathology Mechanisms](/mechanisms/tau-pathology)
[Anti-Tau Immunotherapy](/therapeutics/anti-tau-immunotherapies)
[Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-disease-biomarkers)
[Flortaucipir PET](/clinical-trials/flortaucipir-ad-nct02580308)
[PI-2620 Tau PET](/clinical-trials/pi-2620-tau-psp-nct04144951)
[MK-6240 Tau PET](/clinical-trials/mk-6240-tau-phase3-nct04374158)

[Tau Phosphorylation Pathway](/mechanisms/tau-phosphorylation)
[Neurofibrillary Tangle Formation](/mechanisms/nft-formation)
[Tau Spread Mechanisms](/mechanisms/tau-spread-prion-like)

[Amyloid PET Imaging](/diagnostics/amyloid-pet)
[FDG-PET in Dementia](/diagnostics/fdg-pet-dementia)
[CSF Biomarkers](/diagnostics/csf-biomarkers)

Competitive Landscape: Tau PET Tracers

First-Generation vs Second-Generation Comparison

The development of tau PET tracers has evolved through distinct generations, each addressing limitations of previous approaches[@leuzy2021]:

First-Generation Tracers (e.g., Flortaucipir, AV-1451):

Developed primarily for Alzheimer's disease tau (3R/4R PHF)
Limited binding to 4R tauopathies (PSP, CBD)
Significant off-target binding to melanin and choroid plexus
Complex kinetic modeling requirements

Second-Generation Tracers (e.g., APN-1607, PI-2620, MK-6240):

Broader isoform binding (3R and 4R)
Reduced off-target binding
Improved signal-to-background ratios
More favorable kinetics for clinical implementation

Clinical Development Pipeline

| Tracer | Company | Target Profile | Phase | Key Indication |
|--------|---------|----------------|-------|----------------|
| APN-1607 | Aprinoia | 3R/4R tau | Phase 3 | AD, PSP, CBD |
| Flortaucipir | Avid/Lilly | PHF-tau | Approved | AD |
| PI-2620 | Piramal | 3R/4R tau | Phase 3 | PSP, CBD, AD |
| MK-6240 | Merck | PHF-tau | Phase 3 | AD |
| JN-067 | Janssen | PHF-tau | Phase 2 | AD |

Specificity Considerations

APN-1607 demonstrates distinctive binding properties[@chen2023]:

Tau Filament Specificity:

High affinity for paired helical filaments (PHF)
Binding to straight filaments (SF)
Distinction between 3R and 4R tau isoforms

Off-Target Minimization:

Reduced affinity for neuromelanin
Minimal binding to MAO enzymes
Lower non-specific background

Technical Considerations for Clinical Implementation

Image Acquisition Protocols

Standardized protocols ensure consistent results across sites[@johnson2023]:

Injection Parameters:

Dose: 185-370 MBq (5-10 mCi)
Specific activity: >37 GBq/μmol
Radiochemical purity: >95%

Acquisition Settings:

Emission scan: 90-110 min post-injection
Duration: 20-30 minutes
Reconstruction: OSEM with attenuation correction
Matrix: 256 × 256

Quality Control Requirements

Rigorous QC ensures reliable results:

Tracer Requirements:

pH: 5.5-8.0
Endotoxins: <10 EU/mL
Sterility: No growth at 14 days
Radiochemical purity: >95%

Image Quality Standards:

Spatial resolution: <3 mm
Signal-to-noise ratio: >10
Motion artifacts: <2mm displacement

Quantification Challenges

SUVR measurements require careful approach:

Reference Region Selection:

Cerebellar cortex: Standard for AD
Whole cerebellum: Alternative reference
Pons: Used for some 4R tauopathies

Partial Volume Effects:

Correct for atrophy in advanced disease
Use PVC algorithms when available
Consider region-specific thresholds

Clinical Utility in Therapeutic Development

Patient Selection for Clinical Trials

Tau PET enables enrichment strategies for anti-tau therapeutic trials:

Eligibility Criteria:

Tau-positive status by PET
Defined tau burden thresholds
Braak stage-appropriate inclusion

Stratification Biomarkers:

Regional tau burden levels
Tau spread patterns
Co-pathology assessment (amyloid, α-syn)

Target Engagement Assessment

Demonstrating drug-tau interaction requires:

Dose-Occupancy Studies:

Pre-treatment baseline scans
Post-treatment occupancy scans
Relationship to plasma PK

Biomarker Correlation:

Changes in PET signal
CSF tau markers
Clinical outcome correlations

Efficacy Monitoring

Longitudinal tau PET serves as:

Trial Endpoints:

Change in SUVR from baseline
Regional burden progression rates
Tau spread patterns over time

Decision-Making Criteria:

Go/no-go decision points
Dose-selection decisions
Registration trial eligibility

Regulatory Status and Reimbursement

FDA Approval Considerations

Flortaucipir (Tauvid) approval established precedent:

Approved Indications:

Tau PET in Alzheimer's disease
Not for other tauopathies
Not for standalone diagnosis

APN-1607 Differentiation:

4R tauopathy indication potential
Broader disease spectrum
Improved specificity

Insurance Coverage

Reimbursement pathways are evolving:

Medicare Coverage:

Limited to specific clinical scenarios
Prior authorization often required
Coverage varies by region

Research and Clinical Trial Use:

Often covered under research protocols
Central imaging contract requirements
Standard of care in specialized centers

Emerging Applications and Research Directions

Combining tau PET with other imaging modalities provides comprehensive assessment:

Tau + Amyloid PET:

Simultaneous assessment of both pathologies
Understanding co-pathology effects
Better prediction of clinical outcomes

Tau PET + MRI:

atrophy correction for PET signals
Regional specificity validation
Neurodegeneration correlation

Tau PET + FDG-PET:

Relationship between tau and hypometabolism
Network-level dysfunction mapping
Treatment response assessment

Quantitative Advances

New analytical methods improve precision:

Longitudinal Analysis:

Annualized rate of change metrics
Individual slope estimation
Predictive modeling

Machine Learning Applications:

Automated ROI delineation
Pattern recognition for disease staging
Outcome prediction models

Patient Perspectives and Clinical Implementation

Practical Considerations for Patients

Undergoing tau PET involves several considerations:

Procedure Experience:

90-110 minute wait after injection
20-30 minute scan duration
Minimal discomfort
Radiation exposure comparable to CT

Preparation Requirements:

Fasting not typically required
Hydration encouraged post-scan
Continue regular medications
Avoid caffeine for limited period

Clinical Decision-Making Integration

Tau PET results inform management:

Diagnostic Clarity:

Confirmation of Alzheimer's vs other dementias
Differentiation of tauopathy subtypes
Understanding atypical presentations

Treatment Planning:

Anti-amyloid therapy eligibility assessment
Prognostic counseling
Clinical trial enrollment

External Links

[ClinicalTrials.gov: NCT07422857](https://clinicaltrials.gov/study/NCT07422857)
[Aprinoia Therapeutics](https://www.aprinoia.com/)
[Tau PET Tracer Comparison](https://pubmed.ncbi.nlm.nih.gov/?term=tau+PET+tracers+APN-1607)

References

[Aprinoia Therapeutics Pipeline (2024)](https://www.aprinoia.com/)

[18F-APN-1607 PET Study - ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03625128)

[Characterization of 18F-PM-PBB3 in AD and PSP, Nature Medicine (2024)](https://doi.org/10.1038/s41591-024-03121-2)

[Nikolaychuk et al., Second-generation tau PET tracers, EJNMMI Radiopharmacy (2023)](https://pubmed.ncbi.nlm.nih.gov/37145678/)

[Leuzy et al., Tau PET imaging in Alzheimer's disease, Nature Reviews Neurology (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Smith et al., Comparison of tau PET tracers in 4R tauopathies, Brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Johnson et al., Tau PET quantitation methods, Journal of Nuclear Medicine (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Marion et al., Clinical validation of 18F-APN-1607, Alzheimer's & Dementia (2024)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Chen et al., 18F-APN-1607 binding characteristics, European Journal of Nuclear Medicine (2023)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Hostetler et al., Radiation dosimetry of 18F-APN-1607, Radiation Dosimetry (2023)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Su et al., Test-retest reliability of 18F-APN-1607 PET, European Journal of Nuclear Medicine (2023)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Yoon et al., Correlation of 18F-APN-1607 with CSF biomarkers, Annals of Neurology (2024)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Krismer et al., Tau PET in differential diagnosis of dementias, Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Haight et al., Longitudinal changes in tau PET, Nature Aging (2023)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Ossenkoppele et al., Tau PET patterns predict clinical progression, JAMA Neurology (2021)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Scholl et al., Tau PET and neurodegeneration, Neuron (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Farrell et al., Centiloid scale standardization, Alzheimer's & Dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Gomolin et al., Automated quantification of tau PET, Neuroimage (2023)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Leuzy et al., Tau PET in 4R tauopathies, Movement Disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Bullich et al., Kinetic modeling for tau PET, Journal of Cerebral Blood Flow (2023)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Villemagne et al., Tau PET imaging in aging and neurodegeneration, Brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Baker et al., Tau PET in preclinical AD, Nature Neuroscience (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Iaccarino et al., Tau PET and cognitive decline, JAMA Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Bejanin et al., Tau pathology and neurodegeneration, Brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Pontecorvo et al., Tau PET flortaucipir validation, Alzheimer's & Dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

📖 View canonical wiki page →

Related Entities

clinical-trials-apn-1607-tau-pet-phase3-nct07422857

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-apn-1607-tau-pet-phase3-nct07422857
kg_node_id	None
entity_type	clinical_trial
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-3575e47118f2
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-apn-1607-tau-pet-phase3-nct07422857'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

65%

Debates

0

Incoming

13

Outgoing

17

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

apn-1607-tau-pet-phase3-nct07422857

APN-1607 Tau PET Phase 3 Trial (NCT07422857)

Overview

APN-1607 Tau PET Phase 3 Trial (NCT07422857)

Overview

Trial Details

Background: Tau PET Imaging in Neurodegeneration

The Importance of Tau Pathology

First-Generation Tau PET Tracers

Second-Generation Tau PET Tracers

Key Advantages of APN-1607

Mechanism of Action

APN-1607 Binding Characteristics

Signal Generation

Study Objectives and Endpoints

Primary Endpoints

Secondary Endpoints

Exploratory Objectives

Patient Population

Inclusion Criteria

Exclusion Criteria

Imaging Protocol

PET Acquisition

Quantification Methods

Clinical Significance

Diagnostic Applications

Therapeutic Development Applications

Comparison with Other Tracers

Scientific Rationale

Biological Basis for Tau Imaging

Technical Advantages of APN-1607

Clinical Validation Studies

Phase 1 and 2 Findings

Published Clinical Evidence

Safety Profile

Radiation Considerations

Adverse Events

Future Directions

Broader Clinical Applications

Combination with Therapeutic Trials

Cross-References

Related Pages

Related Mechanisms

Related Diagnostics

Competitive Landscape: Tau PET Tracers

First-Generation vs Second-Generation Comparison

Clinical Development Pipeline

Specificity Considerations

Technical Considerations for Clinical Implementation

Image Acquisition Protocols

Quality Control Requirements

Quantification Challenges

Clinical Utility in Therapeutic Development

Patient Selection for Clinical Trials

Target Engagement Assessment

Efficacy Monitoring

Regulatory Status and Reimbursement

FDA Approval Considerations

Insurance Coverage

Emerging Applications and Research Directions

Multi-Modal Imaging Approaches

Quantitative Advances

Patient Perspectives and Clinical Implementation

Practical Considerations for Patients

Clinical Decision-Making Integration

External Links

References

💬 Discussion